Solriamfetol · Sunosi

Small molecule

Also known as JZP-110

Approvedregulatory verdict

Evidence outlook

Approved: Narcolepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Major Depressive Disorder · Phase 3 · investigational in the USAttention Deficit Hyperactivity Disorder · Phase 3 · investigational in the US

Also approved (2)
CA
  • Excessive daytime sleepiness in adults with narcolepsy and in adults with obstructive sleep apnea
Product first approved 2021dhpp.hpfb-dgpsa.ca
EU
  • Improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnoea
Product first approved 2020EMA

Development in Parkinson's Disease stopped for reasons the sponsor has not stated. Source

Company guidance: topline data expected 1H 2027 (NCT07484217; Axsome Therapeutics, 2 Nov 2026). “Placebo Solriamfetol (150 mg) Solriamfetol for the treatment of MDD with EDS symptoms Key eligibility criteria 18-65 years of age with diagnosis of MDD (DSM-5 criteria) Symptoms of excessive daytime sleepiness Double-blind phase Primary endpoint Time from randomization to relapse of depressive symptoms Solriamfetol (150 mg) CLARITY Phase 3 trial Open-label period Baseline 1:1 randomization (Patients achieving treatment response) 38 1:1 R Enrollment completion anticipated 1H 2027” Source ↗

Company guidance: topline data expected 2H 2027 (Axsome Therapeutics, 2 Nov 2026). “Solriamfetol for the treatment of shift work disorder Key eligibility criteria 18-65 years of age with diagnosis of SWD (ICSD-2 or ICSD-3) Primary endpoint Change from baseline in MWT Placebo Solriamfetol (150 mg) Screening (1-4 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R N=450 Follow-up (1 week) SUSTAIN Phase 3 trial Topline results anticipated 2H 2027 MWT = Maintenance of Wakefulness Test 36” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (14)
Attention Deficit Hyperactivity Disorder
NCT07717879 · Axsome Therapeutics, Inc.
2026-07-06 – 2028-06-30 · ADHD
What this study did
NCT07717892 · Axsome Therapeutics, Inc.
2026-06-25 – 2028-06-30 · ADHD
What this study did
NCT07773883 · Axsome Therapeutics, Inc.
2026-08-06 – 2027-12 · ADHD
What this study did
Major Depressive Disorder
Narcolepsy
Other / comorbidity
NCT06878976 · Axsome Therapeutics, Inc.
2025-02-20 – 2027-12 · Binge-Eating Disorder
What this study did
NCT06568367 · Axsome Therapeutics, Inc.
2024-08-01 – 2026-12 · Excessive Sleepiness, Shift-work Disorder
What this study did
NCT06413433 · Axsome Therapeutics, Inc.
2024-04-26 – 2026-12 · Binge-Eating Disorder
What this study did
NCT02348606 · Jazz Pharmaceuticals
2015-05 – 2016-12 · Obstructive Sleep Apnea
What this study did
Phase 2/3 (1)
Attention Deficit Hyperactivity Disorder
NCT04839562 · Massachusetts General Hospital
2021-08-06 – 2023-01-27 · Attention Deficit Hyperactivity Disorder
What this study did
Phase 2 (8)
Narcolepsy
NCT02806908 · Jazz Pharmaceuticals
2016-06 – 2019-05-19 · Narcolepsy, Excessive Sleepiness
What this study did
Other / comorbidity
NCT06590662 · University Hospital, Montpellier
2024-09-15 – 2027-06-01 · Idiopathic Hypersomnia
What this study did
NCT06170970 · Johns Hopkins University
2024-06-01 – 2027-03-01 · Multiple Sclerosis, Multiple Sclerosis Fatigue
What this study did
NCT06404099 · Duke University
2024-08-12 – 2026-04-20 · Long COVID, Long COVID-19, Hypersomnia
What this study did
NCT06404086 · Duke University
2024-07-31 – 2025-12-31 · Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
What this study did
NCT03868943 · Wake Forest University Health Sciences
2021-01-27 – 2021-11-22 · Glioma, Glioblastoma
What this study did
NCT02806895 · Jazz Pharmaceuticals
2016-07-05 – 2019-05-28 · Obstructive Sleep Apnea, Excessive Sleepiness
What this study did
NCT03037203 · Jazz Pharmaceuticals
2017-01 – 2018-08 · Excessive Sleepiness, Parkinson Disease
What this study did
Phase 1 (1)
Narcolepsy
NCT05008341 · Axsome Therapeutics, Inc.
2021-08-27 – 2022-04-15 · Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
What this study did
Phase 4 (5)
Other / comorbidity
NCT05838430 · University of Pennsylvania
2023-07-31 – 2026-04-30 · Insomnia
What this study did
NCT04602936 · Lindner Center of HOPE
2021-06-15 – 2024-12-30 · Binge Eating Disorder
What this study did
NCT04622293 · Rochester Center for Behavioral Medicine
2021-04-27 – 2024-12-01 · Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
What this study did
NCT04788953 · Charles A. Czeisler, PhD, MD
2021-07-21 – 2024-04-19 · Excessive Sleepiness, Shift-work Disorder
What this study did
NCT04789174 · Axsome Therapeutics, Inc.
2021-05-17 – 2022-09-19 · Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Attention Deficit Hyperactivity Disorder: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Solriamfetol (Sunosi): this drugPhase 3Small moleculeDopamine/norepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
Centanafadine (Simtriyo)ApprovedSmall moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint
Naltrexone / Bupropion (Contrave)
Approved(overall)
Small moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporter
not yet graded(overall)
No reviewed efficacy summary in this indication
Viloxazine (Qelbree)ApprovedSmall moleculenorepinephrine transporterReliable signal
NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91)
NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52)
Lysergide Tartrate (LSD) (DT120)Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sunosi (Solriamfetol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 3Excessive Sleepiness, Shift-work DisorderRecruiting
Est. primary completion 2026-12 · NCT06568367 · CT.gov ↗
What to watch
Phase 3Binge-Eating DisorderRecruiting
Est. primary completion 2026-12 · NCT06413433 · CT.gov ↗
What to watch
Phase 2Multiple Sclerosis, Multiple Sclerosis FatigueRecruiting
Est. primary completion 2026-12-01 · NCT06170970 · CT.gov ↗
What to watch
2027 (2)
December 2027 (2)
Phase 3Attention Deficit Hyperactivity DisorderEnrolling by invitation
Est. primary completion 2027-12 · NCT07773883 · CT.gov ↗
What to watch
Phase 3Binge-Eating DisorderEnrolling by invitation
Est. primary completion 2027-12 · NCT06878976 · CT.gov ↗
What to watch
2028 (3)
June 2028 (2)
Phase 3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2028-06-30 · NCT07717879 · CT.gov ↗
What to watch
Phase 3Attention Deficit Hyperactivity DisorderRecruiting
Est. primary completion 2028-06-30 · NCT07717892 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2028-12 · NCT07484217 · CT.gov ↗

Company guidance: topline data expected 1H 2027 (Axsome Therapeutics, 2 Nov 2026). “Placebo Solriamfetol (150 mg) Solriamfetol for the treatment of MDD with EDS symptoms Key eligibility criteria 18-65 years of age with diagnosis of MDD (DSM-5 criteria) Symptoms of excessive daytime sleepiness Double-blind phase Primary endpoint Time from randomization to relapse of depressive symptoms Solriamfetol (150 mg) CLARITY Phase 3 trial Open-label period Baseline 1:1 randomization (Patients achieving treatment response) 38 1:1 R Enrollment completion anticipated 1H 2027” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 March 2025Topline resultFOCUS Phase 3 of solriamfetol in adult ADHD (NCT05972044) met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗